Ruffo Freitas-Junior on Muck Rack

Ruffo Freitas-Junior

As seen in: Nature, ONCOLOGY journal, eCancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruffo

Contact Ruffo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ruffo Freitas-Junior

|
By Ruffo Freitas-Junior
| ONCOLOGY journal Verified
Articles by Ruffo Freitas-Junior 130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study BySara M. Tolaney, MD, MPH,Evandro de Azambuja,Kevin Kalinsky, MD, MS,Sherene Loi, MD, PhD,Sung-Bae Kim,Clinton Yam,Bernardo Rapoport, MD,Seock-Ah Im,Barbara Pistilli,Wassim McHayleh,David W.
Open in Who Shared View Duplicates (5) Issue with article?

Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort - Scientific Reports

|
By André Mattar, Marcelo Antonini, Francisco Pimentel Cavalcante, Felipe Pereira Zerwes, Eduardo Camargo Millen, Fabricio Palermo Brenelli, Antonio Luiz Frasson, Marcelo Madeira, Marina Diogenes Teixeira, Andressa Amorim, Ruffo Freitas-Junior, Henrique Couto, Leandro Alves, Renata Leite, Leonardo Ribeiro Sorares, Gil Facina, Rogerio Fenile, Renata Arakelian
| Nature Verified
Abstract Breast cancer (BC) is the most prevalent cancer among Brazilian women, yet related data remain limited. The HER2-low classification has gained significance with the advent of targeted therapies. This study aimed to assess survival outcomes of HER2-low BC compared to other subtypes in a real-world Brazilian cohort. We analyzed data from 8,485 breast cancer patients treated at Pérola Byington Hospital between 2010 and 2019.
Open in Who Shared Issue with article?

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥70 years with ultralow risk of distant recurrence: A population-based cohort study - PubMed

|
By Ruffo Freitas-Junior, Mansani FP, Freitas-Junior R, Fabio P Mansani
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (599) Issue with article?
See all 7 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified